2 weeks ago

Single-Shot Gene Editing Treatment Targets Cholesterol Through PCSK9

Single-Shot Gene Editing Treatment Targets Cholesterol Through PCSK9
A Single Shot to Lower Bad Cholesterol? The Verve-102 Gene-Editing Breakthrough Explained · timesnownews.com

LDL is often called bad cholesterol.

People with very high LDL commonly take statin medicines for many years.

Researchers are testing a different idea called gene editing.

Verve-102 is an experimental treatment for this purpose.

It would be given through one intravenous infusion.

The treatment is designed to work on the PCSK9 gene in liver cells.

It uses a method called in vivo base editing.

This method aims to make a precise change to DNA inside the body.

The goal is to lower LDL cholesterol after a single treatment.

Key facts

Treatment
Verve-102
Target
The PCSK9 gene in liver cells
Editing method
In vivo base editing
Administration
A single intravenous infusion
Intended effect
Lower LDL cholesterol
Current status
Experimental

Sources

Related news